Key result
In Russian patients at high cardiovascular risk, antihypertensive medications were used in 92.1% and lipid-lowering drugs in 18%, compared to 82.7% and 35.6% in the overall European study cohort.
Why the study?
What are the features of drug and non-drug therapy for primary cardiovascular prevention in high-risk patients in Russia compared to other European countries?
Cross-Sectional (n=505)
Yes
What are the features of drug and non-drug therapy for primary cardiovascular prevention in high-risk patients in Russia compared to other European countries?
There is considerable room for improvement in primary cardiovascular disease prevention, particularly regarding the underutilization of lipid-lowering therapies in high-risk patients.
Background. The picture of primary prevention obtained from real-life practice makes possible scheduling measures for prevention improvement. Aim. To analyze features of drug and non-drug therapy aimed at decreasing cardiovascular risk in Russian patients with a high risk (HR) of CVD compared with the study general population. Materials and methods. 14 European countries, including the Russian Federation, participated in this cross-sectional study. The study included patients aged 18-80 without clinical signs of atherosclerosis who have received antihypertensive and/or lipid-lowering therapy and/or therapy for diabetes mellitus (DM) within >6 to 1c . Oral glucose tolerance test was performed for all patients without fasting hyperglycemia of >11.1 mmol/l. Results. In total, 505 patients with HR were evaluated at Russian study sites and 405 interviews (71.6% females) were taken. Both in the Russian cohort and other countries, the most common recommendations for correction of overweight and obesity concerned diet and physical activity; a drug therapy was administered extremely rarely. Proportion of targeted exercise was approximately similar in the Russian cohort and the study as a whole, 16-18%. Antihypertensive medications were administered to 92.1% of patients in the Russian cohort and 82.7% of patients in the entire study. The most popular classes of antihypertensive drugs were beta-blockers (39.9% and 36.8% respectively), ACEI/ARB (79.6% and 79.8%), calcium antagonists (14.7% and 29.1%), and diuretics (26% and 38.3%). 18% and 35.6% of patients, respectively, received lipid-lowering drugs, and these drugs were statins in 89% and 96.1% of cases. Antihyperglycemic therapy was represented by oral drugs in 70.8% and 75.1% respectively; 16.7% and 18.3% of patients received insulin. Generally, patients estimated their compliance with the drug therapy rather highly. Conclusion. Results of the primary care arm of the EUROASPIRE IV survey indicate considerable room for improvement of CVD prevention.
No takes yet. Share an insight, caveat, or question.
Pogosova et al. (2017) conducted a cross-sectional in High cardiovascular risk (n=505). Primary prevention therapies (Russian cohort) vs. Primary prevention therapies (Overall European cohort) was evaluated on Antihypertensive medication use. In Russian patients at high cardiovascular risk, antihypertensive medications were used in 92.1% and lipid-lowering drugs in 18%, compared to 82.7% and 35.6% in the overall European study cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: